002737 葵花药业
交易中 02-09 10:25:15
资讯
新帖
简况
葵花药业：2月6日接受机构调研，中金银海(香港)基金有限公司、中润国信投资基金参与
证券之星 · 09:01
葵花药业：2月6日接受机构调研，中金银海(香港)基金有限公司、中润国信投资基金参与
股市必读：葵花药业（002737）2月2日董秘有最新回复
证券之星 · 02-03
股市必读：葵花药业（002737）2月2日董秘有最新回复
葵花药业(002737.SZ)易活牌益生菌粉注册申请获受理
智通财经 · 02-02
葵花药业(002737.SZ)易活牌益生菌粉注册申请获受理
葵花药业：公司坚持“买、改、联、研”的特色组合研发战略
证券之星 · 02-02
葵花药业：公司坚持“买、改、联、研”的特色组合研发战略
葵花药业（002737）披露2025年度业绩预告，1月29日股价下跌0.21%
证券之星 · 01-29
葵花药业（002737）披露2025年度业绩预告，1月29日股价下跌0.21%
股市必读：葵花药业（002737）1月21日董秘有最新回复
证券之星 · 01-22
股市必读：葵花药业（002737）1月21日董秘有最新回复
葵花药业（002737）披露使用闲置自有资金进行现金管理进展公告，1月20日股价上涨0.27%
证券之星 · 01-20
葵花药业（002737）披露使用闲置自有资金进行现金管理进展公告，1月20日股价上涨0.27%
葵花药业：截至2025年12月31日股东人数为4.8万
证券之星 · 01-08
葵花药业：截至2025年12月31日股东人数为4.8万
葵花药业（002737）披露全资子公司受让美沙拉秦肠溶片上市许可及相关生产技术，12月31日股价下跌0.27%
证券之星 · 2025-12-31
葵花药业（002737）披露全资子公司受让美沙拉秦肠溶片上市许可及相关生产技术，12月31日股价下跌0.27%
葵花药业：截至12月19日股东人数为4.9万
证券之星 · 2025-12-24
葵花药业：截至12月19日股东人数为4.9万
葵花药业：截至12月10日股东人数为5.1万
证券之星 · 2025-12-15
葵花药业：截至12月10日股东人数为5.1万
葵花药业（002737）披露对外捐赠议案，12月9日股价下跌1.36%
证券之星 · 2025-12-09
葵花药业（002737）披露对外捐赠议案，12月9日股价下跌1.36%
葵花药业：截至11月28日股东人数为5.1万
证券之星 · 2025-12-03
葵花药业：截至11月28日股东人数为5.1万
葵花药业：截至2025年11月20日股东人数5.2万
证券之星 · 2025-11-27
葵花药业：截至2025年11月20日股东人数5.2万
葵花药业（002737）披露关于注销全资子公司的进展公告，11月25日股价上涨0.68%
证券之星 · 2025-11-25
葵花药业（002737）披露关于注销全资子公司的进展公告，11月25日股价上涨0.68%
葵花药业（002737）披露关于2022年员工持股计划股份出售完毕暨终止的公告，11月24日股价上涨0.55%
证券之星 · 2025-11-24
葵花药业（002737）披露关于2022年员工持股计划股份出售完毕暨终止的公告，11月24日股价上涨0.55%
葵花药业：呼吸抗感领域拥有儿童及成人用药品种
证券之星 · 2025-11-18
葵花药业：呼吸抗感领域拥有儿童及成人用药品种
葵花药业（002737）披露使用闲置自有资金进行现金管理进展公告，11月17日股价下跌0.73%
证券之星 · 2025-11-17
葵花药业（002737）披露使用闲置自有资金进行现金管理进展公告，11月17日股价下跌0.73%
利尔化学(002737.SZ)控股股东拟通过公开征集受让方的方式协议转让公司部分股份
智通财经 · 2025-11-14
利尔化学(002737.SZ)控股股东拟通过公开征集受让方的方式协议转让公司部分股份
葵花药业(002737.SZ)：复方聚乙二醇(3350)电解质散取得药品注册证书
智通财经 · 2025-11-14
葵花药业(002737.SZ)：复方聚乙二醇(3350)电解质散取得药品注册证书
加载更多
公司概况
公司名称：
葵花药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2014-12-30
主营业务：
葵花药业集团股份有限公司的主营业务是中成药、“化学药、生物药”和“健康养生品”的研发、制造与营销。公司的主要产品是中成药、化学药、生物药和健康养生品。报告期内，公司蝉联“第11届品牌强国论坛”-2025中国品牌500强榜单，经权威机构评估，公司“葵花”+“小葵花”品牌价值升至365.78亿元，“双品牌伞”优势进一步凸显，筑牢高质量发展格局。
发行价格：
36.53
{"stockData":{"symbol":"002737","market":"SZ","secType":"STK","nameCN":"葵花药业","latestPrice":14.25,"timestamp":1770603915000,"preClose":14.3,"halted":0,"volume":1569700,"delay":0,"changeRate":-0.0035,"floatShares":584000000,"shares":584000000,"eps":-0.2198,"marketStatus":"交易中","change":-0.05,"latestTime":"02-09 10:25:15","open":14.26,"high":14.37,"low":14.19,"amount":22336700,"amplitude":0.0126,"askPrice":14.27,"askSize":6,"bidPrice":14.25,"bidSize":134,"shortable":0,"etf":0,"ttmEps":-0.2198,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770607800000},"marketStatusCode":2,"adr":0,"adjPreClose":14.3,"symbolType":"stock","openAndCloseTimeList":[[1770600600000,1770607800000],[1770613200000,1770620400000]],"highLimit":15.73,"lowLimit":12.87,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":584000000,"isCdr":false,"pbRate":2.06,"roa":"--","roe":"--","epsLYR":0.84,"committee":-0.118367,"marketValue":8322000000,"turnoverRate":0.0027,"status":1,"floatMarketCap":8322000000},"requestUrl":"/m/hq/s/002737","defaultTab":"news","newsList":[{"id":"2610509565","title":"葵花药业：2月6日接受机构调研，中金银海(香港)基金有限公司、中润国信投资基金参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2610509565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610509565?lang=zh_cn&edition=full","pubTime":"2026-02-09 09:01","pubTimestamp":1770598860,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年2月8日葵花药业发布公告称公司于2026年2月6日接受机构调研，中金银海(香港)基金有限公司雍心 郭佳怡、中润国信投资基金崔建民参与。公司高管变动系正常人员流动，具体变动原因公司已在公告中进行披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900001466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002737","BK0028"],"gpt_icon":0},{"id":"2608891743","title":"股市必读：葵花药业（002737）2月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2608891743","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608891743?lang=zh_cn&edition=full","pubTime":"2026-02-03 02:26","pubTimestamp":1770056771,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，葵花药业报收于13.98元，下跌0.71%，换手率0.67%，成交量3.9万手，成交额5491.07万元。公司公告汇总关于收到易活牌益生菌粉注册申请受理通知书的公告葵花药业集团股份有限公司全资子公司哈尔滨葵花药业有限公司近日收到国家市场监督管理总局下发的关于“易活牌益生菌粉”注册申请的《受理通知书》，受理号为国食健申G20260026，申请事项为国产保健食品新产品注册。经审查，决定予以受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300001477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0028","BK0239"],"gpt_icon":0},{"id":"2608557148","title":"葵花药业(002737.SZ)易活牌益生菌粉注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2608557148","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608557148?lang=zh_cn&edition=full","pubTime":"2026-02-02 15:55","pubTimestamp":1770018910,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)公告，公司全资子公司哈尔滨葵花药业有限公司于近日收到国家市场监督管理总局下发的关于“易活牌益生菌粉”注册申请的《受理通知书》。公告称，本品经动物实验评价，具有有助于增强免疫力的保健功能;有助于润肠通便。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","002737"],"gpt_icon":0},{"id":"2608785364","title":"葵花药业：公司坚持“买、改、联、研”的特色组合研发战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2608785364","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608785364?lang=zh_cn&edition=full","pubTime":"2026-02-02 15:18","pubTimestamp":1770016709,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业02月02日在投资者关系平台上答复投资者关心的问题。2025年，公司在研发领域取得多项成果。同时，公司多款药品及大健康产品申请注册上市许可获得受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200015383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0028","BK0239"],"gpt_icon":0},{"id":"2607039483","title":"葵花药业（002737）披露2025年度业绩预告，1月29日股价下跌0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607039483","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607039483?lang=zh_cn&edition=full","pubTime":"2026-01-29 23:18","pubTimestamp":1769699892,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，葵花药业报收于14.39元，较前一交易日下跌0.21%，最新总市值为84.04亿元。该股当日开盘14.38元，最高14.45元，最低14.24元，成交额达5332.11万元，换手率为0.64%。近日，葵花药业集团股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为-38,000万元至-24,000万元，较上年同期下降177.23%至148.78%；扣除非经常性损益后的净利润为-42,000万元至-28,500万元，同比下降221.84%至182.68%。最终数据以2025年年度报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900044422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002737"],"gpt_icon":0},{"id":"2605948799","title":"股市必读：葵花药业（002737）1月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2605948799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605948799?lang=zh_cn&edition=full","pubTime":"2026-01-22 03:03","pubTimestamp":1769022192,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，葵花药业报收于14.63元，下跌1.01%，换手率0.54%，成交量3.18万手，成交额4668.12万元。当日关注点来自交易信息汇总：1月21日主力资金净流出287.21万元，游资资金净流入278.67万元。来自公司公告汇总：葵花药业使用闲置自有资金65,000万元购买理财产品，预期年化收益率为1.6%-2.1%。公司已履行相关决策程序，授权董事长行使决策权，财务部门负责实施。截至公告日，未到期现金管理金额为185,000万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200001194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0028","BK0239"],"gpt_icon":0},{"id":"2604211111","title":"葵花药业（002737）披露使用闲置自有资金进行现金管理进展公告，1月20日股价上涨0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604211111","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604211111?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:33","pubTimestamp":1768919590,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘，葵花药业报收于14.78元，较前一交易日上涨0.27%，最新总市值为86.32亿元。该股当日开盘14.74元，最高14.78元，最低14.69元，成交额达3780.31万元，换手率为0.44%。公司近日发布公告称，葵花药业集团股份有限公司使用闲置自有资金65,000万元购买理财产品，包括浦银理财、民生理财和兴银理财产品，投资期限从2026年1月20日起，预期年化收益率为1.6%-2.1%。资金来源为闲置自有资金，不涉及关联交易。截至公告日，未到期现金管理金额为185,000万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000039827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002737","BK0239"],"gpt_icon":0},{"id":"2601599483","title":"葵花药业：截至2025年12月31日股东人数为4.8万","url":"https://stock-news.laohu8.com/highlight/detail?id=2601599483","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601599483?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:03","pubTimestamp":1767859391,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业(002737)01月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司董秘，截止2025年末，股东人数有多少，谢谢！！！葵花药业回复：截至2025年12月31日，公司股东人数为4.8万，感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800021120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002737"],"gpt_icon":0},{"id":"2595778290","title":"葵花药业（002737）披露全资子公司受让美沙拉秦肠溶片上市许可及相关生产技术，12月31日股价下跌0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778290","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595778290?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:13","pubTimestamp":1767176033,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，葵花药业报收于14.77元，较前一交易日下跌0.27%，最新总市值为86.26亿元。公司近日发布公告称，于2025年12月30日召开第五届董事会第十五次会议，审议通过全资子公司葵花药业集团佳木斯鹿灵制药有限公司以人民币3,400万元（含税）受让合肥立方制药股份有限公司持有的美沙拉秦肠溶片药品上市许可及相关生产技术。上市许可持有人变更尚需国家药品监督管理局审批。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100034039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0028","BK0239"],"gpt_icon":0},{"id":"2593842002","title":"葵花药业：截至12月19日股东人数为4.9万","url":"https://stock-news.laohu8.com/highlight/detail?id=2593842002","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593842002?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:36","pubTimestamp":1766565377,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业(002737)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至12月20日公司的股东人数是多少？谢谢葵花药业回复：截至12月19日，公司股东人数为4.9万，感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400024362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0028","BK0239"],"gpt_icon":0},{"id":"2591197376","title":"葵花药业：截至12月10日股东人数为5.1万","url":"https://stock-news.laohu8.com/highlight/detail?id=2591197376","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591197376?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:36","pubTimestamp":1765787774,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业(002737)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问股东户数是多少葵花药业回复：截至12月10日，公司股东人数为5.1万，感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500018003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002737","BK0028"],"gpt_icon":0},{"id":"2590527342","title":"葵花药业（002737）披露对外捐赠议案，12月9日股价下跌1.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590527342","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590527342?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:24","pubTimestamp":1765290276,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘，葵花药业报收于14.55元，较前一交易日下跌1.36%，最新总市值为84.97亿元。该股当日开盘14.76元，最高14.8元，最低14.55元，成交额达3596.82万元，换手率为0.42%。近日，葵花药业集团股份有限公司召开第五届董事会第十四次会议，审议通过《关于对外捐赠的议案》。会议表决结果为同意9票，反对0票，弃权0票，议案获得通过。该事项属于董事会审议权限，无需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900041002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002737","BK0028"],"gpt_icon":0},{"id":"2588150550","title":"葵花药业：截至11月28日股东人数为5.1万","url":"https://stock-news.laohu8.com/highlight/detail?id=2588150550","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588150550?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:00","pubTimestamp":1764748826,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业(002737)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截至11月30日的股东人数是多少，谢谢葵花药业回复：截至11月28日，公司股东人数为5.1万，感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300019361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002737"],"gpt_icon":0},{"id":"2586915243","title":"葵花药业：截至2025年11月20日股东人数5.2万","url":"https://stock-news.laohu8.com/highlight/detail?id=2586915243","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586915243?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:54","pubTimestamp":1764233667,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业(002737)11月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截至11月20日的股东人数是多少，谢谢葵花药业回复：截至2025年11月20日，公司股东人数5.2万，感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700023900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0028","BK0239"],"gpt_icon":0},{"id":"2586183471","title":"葵花药业（002737）披露关于注销全资子公司的进展公告，11月25日股价上涨0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586183471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586183471?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:32","pubTimestamp":1764081159,"startTime":"0","endTime":"0","summary":"截至2025年11月25日收盘，葵花药业报收于14.73元，较前一交易日上涨0.68%，最新总市值为86.02亿元。此次注销事项源于葵花药业于2025年7月25日召开的第五届董事会第八次会议审议通过的相关议案，旨在优化投资控股体系、缩短管理链条、整合资源并降低运营成本。公告指出，本次注销不会对公司整体财务和经营状况产生重大影响，不存在损害公司及股东利益的情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500039596.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002737"],"gpt_icon":0},{"id":"2585498125","title":"葵花药业（002737）披露关于2022年员工持股计划股份出售完毕暨终止的公告，11月24日股价上涨0.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498125","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585498125?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:30","pubTimestamp":1763994659,"startTime":"0","endTime":"0","summary":"近日，葵花药业发布关于2022年员工持股计划股份出售完毕暨终止的公告。公告称，公司于2022年8月实施2022年员工持股计划，并于2022年10月27日完成2,950,060股非交易过户至员工持股计划，占公司总股本的0.51%。该员工持股计划存续期为48个月，分三期解锁，解锁比例分别为30%、35%、35%。截至公告日，员工持股计划所持有的公司股份已全部通过集中竞价方式出售完毕，员工持股计划提前终止，后续将进行财产清算与分配。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400036040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002737"],"gpt_icon":0},{"id":"2584623605","title":"葵花药业：呼吸抗感领域拥有儿童及成人用药品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2584623605","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584623605?lang=zh_cn&edition=full","pubTime":"2025-11-18 08:33","pubTimestamp":1763425992,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业11月17日在投资者关系平台上答复投资者关心的问题。谢谢葵花药业回复：公司产品覆盖“儿童用药、消化系统、呼吸感冒系统、风湿骨病系统、心脑血管系统、妇科、大健康”等治疗领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800006025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0028","BK0239"],"gpt_icon":0},{"id":"2584246036","title":"葵花药业（002737）披露使用闲置自有资金进行现金管理进展公告，11月17日股价下跌0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584246036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584246036?lang=zh_cn&edition=full","pubTime":"2025-11-17 22:35","pubTimestamp":1763390120,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，葵花药业报收于14.97元，较前一交易日下跌0.73%，最新总市值为87.42亿元。该股当日开盘15.09元，最高15.13元，最低14.89元，成交额达5426.6万元，换手率为0.62%。公司近日发布公告称，葵花药业集团股份有限公司使用闲置自有资金进行现金管理，近期使用20,000万元购买招商银行理财产品，期限35天，预期年化收益率2.1%，资金来源为闲置自有资金。截至公告日，未到期现金管理金额为170,000万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700037237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002737"],"gpt_icon":0},{"id":"2583578466","title":"利尔化学(002737.SZ)控股股东拟通过公开征集受让方的方式协议转让公司部分股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2583578466","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583578466?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:01","pubTimestamp":1763107269,"startTime":"0","endTime":"0","summary":"智通财经APP讯，利尔化学 发布公告，2025年11月14日，公司收到控股股东四川久远投资控股集团有限公司《关于拟通过公开征集转让方式转让利尔化学股份有限公司部分股份的告知函》，根据《上市公司国有股权监督管理办法》等有关规定，久远集团拟通过公开征集转让方式转让持有的公司1.6亿股股份，占公司总股本的20%，股份性质为非限售法人股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","002737","BK0186","BK0122","BK0201","002258","BK0229"],"gpt_icon":0},{"id":"2583578339","title":"葵花药业(002737.SZ)：复方聚乙二醇(3350)电解质散取得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2583578339","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583578339?lang=zh_cn&edition=full","pubTime":"2025-11-14 15:54","pubTimestamp":1763106844,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)发布公告，公司子公司于近日收到国家药品监督管理局下发的关于复方聚乙二醇(3350)电解质散获批注册的药品注册证书。复方聚乙二醇(3350)电解质散取得《药品注册证书》后，公司将加速推进新产品的量产与市场投放，进一步拓展产品矩阵，优化产品结构布局，依托品牌资源优势，提升市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葵花药业(002737.SZ)：复方聚乙二醇(3350)电解质散取得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","002737","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770603917271,"stockEarnings":[{"period":"1week","weight":0.0156},{"period":"1month","weight":-0.0403},{"period":"3month","weight":-0.0185},{"period":"6month","weight":-0.1129},{"period":"1year","weight":-0.1839},{"period":"ytd","weight":-0.0318}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"葵花药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"48000人(较上一季度减少2.04%)","perCapita":"12166股","listingDate":"2014-12-30","address":"黑龙江省哈尔滨市道里区高新技术产业开发区迎宾路集中区东湖路18号","registeredCapital":"58400万元","survey":" 葵花药业集团股份有限公司的主营业务是中成药、“化学药、生物药”和“健康养生品”的研发、制造与营销。公司的主要产品是中成药、化学药、生物药和健康养生品。报告期内，公司蝉联“第11届品牌强国论坛”-2025中国品牌500强榜单，经权威机构评估，公司“葵花”+“小葵花”品牌价值升至365.78亿元，“双品牌伞”优势进一步凸显，筑牢高质量发展格局。","listedPrice":36.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葵花药业(002737)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葵花药业,002737,葵花药业股票,葵花药业股票老虎,葵花药业股票老虎国际,葵花药业行情,葵花药业股票行情,葵花药业股价,葵花药业股市,葵花药业股票价格,葵花药业股票交易,葵花药业股票购买,葵花药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葵花药业(002737)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}